Navigation Links
Genmab Discloses Target and Development Plans for HuMax-Inflam
Date:9/13/2007

Summary: Genmab Reveals That HuMax-Inflam Target is IL-8 and Future

Development Will be in Cancer and Inflammation

COPENHAGEN, September 13 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today its fully human HuMax-Inflam(TM) antibody is directed to IL-8 (interleukin-8) and may have potential application in oncology and inflammation. Genmab will initially focus on studies to treat glioblastoma, a cancer of the central nervous system. Other possible indications include chronic obstructive pulmonary disease (COPD) and pustular dermatoses. In pre-clinical studies, HuMax-Inflam has been shown to inhibit tumor growth in tumor models using primary human tumors in immunodeficient mice. HuMax-Inflam was also effective in reducing disease activity in palmoplantar pustulosis patients in a clinical study.

Genmab is currently preparing an improved commercially viable cell line for HuMax-Inflam and hopes to start the next phase of clinical trials in 2008.

"Genmab's development plans for HuMax-Inflam have been a closely guarded secret for several years now and we are happy to announce the solution to the mystery, which has been much anticipated by the investment community," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. "We believe that HuMax-Inflam may have potential to treat patients with glioblastoma, which has a very low survival rate."

About HuMax-Inflam and IL-8

HuMax-Inflam is a high affinity fully human IgG1,k antibody directed towards IL-8. IL-8 is a major mediator of inflammation, a potent chemoattractant for white blood cells called neutrophils, as well as an important factor in angiogenesis. HuMax-Inflam effectively blocks binding of IL-8 to neutrophils and inhibits neutrophils from migrating towards sites of inflammation via a process known as chemotaxis. HuMax-Inflam also potently inhibits IL-8 induced neutrophil activation. In pre-clinical studies, HuMax-Inflam has been shown to inh
'/>"/>

SOURCE Genmab A/S
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Enhanced Amplification of Long Targets with PfuTurbo DNA Polymerase
2. Microarray Target Purification Kit and the Microarray Target Synthesis Kit (T7)
3. Gene Expression Arrays: Highly Sensitive Detection of Expression Patterns with Improved Tools for Target Amplification
4. Detection of antibody-stained cell surface and intracellular protein targets with the Agilent 2100 bioanalyzer
5. Protect RNA and Improve Target Cell Identification
6. Feasibility of Multiplexing Bio-Plex Total Target and Phosphoprotein Assays
7. Development of Radioligand Binding Assays for the Motilin Receptor Using ScreenReady Targets.
8. Calcium Plus Assay Kit, Superior Detection for Specialized Targets
9. ESR1 Gene Expression in Oncology and Metabolic Diseases Using the ASCENTATM System Target Validation and Identification of Novel Disease Indications
10. A Screen of shRNAs Targeting Tumor Suppressor Genes to Identify Factors Involved in Paclitaxel Sensitivity
11. TomoTherapy revises IPO money target
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), ... it has priced an underwritten registered offering of 3,900,000 ... $9.00 per share, and granted the underwriters in the ... additional 585,000 shares of its common stock. The gross ... is expected to close on May 6, 2015, subject ...
(Date:5/1/2015)... -- Investor-Edge has initiated coverage on ... GENE ), Agilent Technologies Inc. (NYSE: A ... ), Sequenom Inc. (NASDAQ: SQNM ), and ... report on Genetic Technologies can be accessed at ... the NASDAQ Composite ended at 4,941.42, down 1.64%, ...
(Date:4/30/2015)... South Carolina (PRWEB) May 01, 2015 ... system services, is extremely proud to announce that for ... been named as a winner of a Queen’s Award ... success for the design and manufacture of a unique ... is the revolutionary alternative to traditional steam flow measurement. ...
(Date:4/30/2015)... , April 30, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... chemicals, today announced that it has commenced an underwritten public ... to grant the underwriters a 30-day option to purchase ... of common stock offered in the public offering. The ... be no assurance as to whether or when the ...
Breaking Biology Technology:BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 3Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 2Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 3Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 4Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 5Spirax Sarco Receives a Queen’s Award for Innovation 2Spirax Sarco Receives a Queen’s Award for Innovation 3BioAmber Inc. Announces Public Offering Of Common Stock 2BioAmber Inc. Announces Public Offering Of Common Stock 3
... International,Corporation (Nasdaq: PRXL ) announced today that ... be presenting at the Thomas,Weisel Partners Healthcare Conference ... September 7th at 8:35 a.m. ET. A live ... "Investor Relations Webcasts",section of PAREXEL,s web site at ...
... 5 Hyperion,Therapeutics, a biopharmaceutical company focused on ... for the,treatment of Urea Cycle Disorders (UCD) and ... B financing. Leading the round was,Sofinnova Ventures, with ... of Menlo Park, CA. WRF Capital of Seattle, ...
... Cryopreservation Expert, BOTHELL, Wash., Sept. 5 ... developer and marketer of,proprietary hypothermic storage and cryopreservation ... the expansion of its Scientific,Advisory Board (SAB) with ... quality and regulatory assurance and in cryopreservation of ...
Cached Biology Technology:PAREXEL International to Present at Thomas Weisel Partners Healthcare Conference 2Hyperion Therapeutics Secures $40 Million In Series B Round 2BioLife Solutions Expands Scientific Advisory Board 2BioLife Solutions Expands Scientific Advisory Board 3BioLife Solutions Expands Scientific Advisory Board 4
(Date:3/24/2015)... 2015   NexID Biometrics LLC, whose spoof-mitigation ... today announced the beginning of shipments of version 2.0 ... The company, based in Potsdam, N.Y. ... Expo, which began here today at the Walter E. ... of its SDK boosts the accuracy rate range to ...
(Date:3/23/2015)... March 23, 2015 SoundView Technology Group issues a ... NXTD ) Wocket smart wallet. SoundView was one of the ... their experience with the Wocket in multiple scenarios and outlets. ... Foods and other retailers, making both debit and credit card ... also says, "If the company meets their plans in 2015, ...
(Date:3/23/2015)... -- In the 2014 fiscal year, irs.gov recorded over $100 ... accounts for a fraction of the estimated losses for ... $11 billion globally. The polygraph has traditionally been used ... Investor Mark Saint Juste along with former ... partnered to administer the test in a new way: ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... unused agricultural land could produce enough biomass to meet ... the environment, according to research led by Professor Gail ... funded by the UK Energy Research Centre (UKERC), is ... at the potential of planting short rotation coppice (poplar ...
... will not only teach us more about the way neurons ... diagnostics and therapies for neurological diseases such as Parkinson,s," says ... take a major toll on society. More than 8% of ... cent suffers from a mental disturbance and the number of ...
... Avila Therapeutics, Inc., a biotechnology company developing novel ... a scientific review article in Nature Reviews Drug ... www.nature.com/reviews/drugdisc , Vol. 10, April 2011, Singh, J.). ... and how structural bioinformatics coupled with structure-based drug design ...
Cached Biology News:Short rotation energy crops could help meet UK's renewable energy targets 2Skywalker ensures optimal communication between neurons 2New opportunities for covalent drugs published by Avila scientists 2
... excluding l-[U-14C]methionine, 1.85 MBq, 50 uCi. ... > 1.85 GBq/mg atom carbon, ... Mixture of Ala, Arg, Asp, Glu, ... Pro, Ser, Thr, Tyr and Val.1.85 ...
Topoisomerase I, isolated from wheat germ, is an enzyme capable of removing negative supercoils from covalently closed circular DNA (1)....
Request Info...
... Checker Kits provide two highly efficient methods ... time-consuming plasmid preparation. By using the large-scale ... need to do is to transfer partial ... the transformation plates into the solutions provided ...
Biology Products: